Drug-Resistant <i>E. coli</i> Bacteremia Transmitted by Fecal Microbiota Transplant
Zachariah DeFilippHesco (United States)Patricia P. BloomLiver Center, Division of GastroenterologyMariam Torres SotoMassachusetts General Hospital, Harvard Medical SchoolMichael K. MansourDivision of Infectious DiseasesMohamad SaterDay Zero DiagnosticsMiriam HuntleyDay Zero DiagnosticsSarah E. TurbettDivision of Infectious DiseasesRaymond T. ChungHesco (United States)Yi‐Bin ChenBlood and Marrow Transplant ProgramElizabeth HohmannFrom the Blood and Marrow Transplant Program (Z.D., Y.-B.C.), the Liver Center, Division of Gastroenterology (P.P.B., R.T.C.), and the Division of Infectious Diseases (M.T.S., M.K.M., S.T., E.L.H.), Massachusetts General Hospital, Harvard Medical School (Z.D., P.P.B., M.T.S., M.K.M., S.T., R.T.C., Y.-B.C., E.L.H.), and Day Zero Diagnostics (M.R.A.S., M.H.H.) — all in Boston
2019en
Ochiq kirishBronza
ABI
Annotatsiya
bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba